Artios
artios is a leading independent dna damage response (ddr) company focussed on developing first-in-class treatments for cancer. established in may 2016, the company is led by an experienced scientific and leadership team with proven expertise in ddr drug discovery. artios is building a pipeline of next-generation ddr programmes, including through a unique partnership with cancer research technology (crt), the development and commercialisation arm of cancer research uk (cruk), and with leading dna repair researchers worldwide. the company’s investors include sv life sciences, merck ventures, imperial innovations, arix bioscience plc, crt pioneer fund (managed by sixth element capital), and abbvie ventures. artios is based at the babraham institute in cambridge, uk.